Dana Investment Advisors Inc. Makes New $482,000 Investment in Mirum Pharmaceuticals, Inc. $MIRM

Dana Investment Advisors Inc. purchased a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 4th quarter, Holdings Channel reports. The firm purchased 6,105 shares of the company’s stock, valued at approximately $482,000.

Several other hedge funds also recently bought and sold shares of MIRM. MCF Advisors LLC increased its position in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at $33,000. Comerica Bank grew its position in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period. Quarry LP purchased a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at $41,000. Finally, CWM LLC grew its position in shares of Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares during the period.

Insider Activity

In other Mirum Pharmaceuticals news, insider Joanne Quan sold 7,287 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $670,258.26. Following the completion of the sale, the insider owned 18,864 shares of the company’s stock, valued at approximately $1,735,110.72. The trade was a 27.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Peter Radovich sold 16,515 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $1,519,049.70. Following the sale, the chief operating officer directly owned 40,272 shares of the company’s stock, valued at approximately $3,704,218.56. This trade represents a 29.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 76,806 shares of company stock valued at $7,064,616 in the last 90 days. 22.87% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $95.65 on Wednesday. The stock has a 50-day moving average price of $95.71 and a two-hundred day moving average price of $87.97. Mirum Pharmaceuticals, Inc. has a 12-month low of $42.89 and a 12-month high of $114.99. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. The company has a market cap of $5.83 billion, a PE ratio of -7.03 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The firm had revenue of $159.88 million for the quarter, compared to analysts’ expectations of $148.21 million. During the same period last year, the firm posted ($0.30) EPS. Mirum Pharmaceuticals’s revenue was up 43.3% on a year-over-year basis. As a group, research analysts predict that Mirum Pharmaceuticals, Inc. will post -2.24 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on MIRM shares. Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Leerink Partners lowered their price objective on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. Royal Bank Of Canada lifted their price objective on Mirum Pharmaceuticals from $128.00 to $142.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Wolfe Research started coverage on Mirum Pharmaceuticals in a research report on Tuesday. They issued an “outperform” rating and a $145.00 price objective for the company. Finally, Evercore reaffirmed an “outperform” rating and issued a $138.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $137.08.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.